[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse GRM3

Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00003 7 transmembrane sweet-taste receptor of 3 GCPR
PF01094 Receptor family ligand binding region
PF07562 Nine Cysteines Domain of family 3 GPCR
Function

G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

> Gene Ontology
 
Biological Process GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007194 negative regulation of adenylate cyclase activity
GO:0007196 adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway
GO:0007215 glutamate receptor signaling pathway
GO:0007216 G-protein coupled glutamate receptor signaling pathway
GO:0007270 neuron-neuron synaptic transmission
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030809 negative regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030818 negative regulation of cAMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031280 negative regulation of cyclase activity
GO:0035249 synaptic transmission, glutamatergic
GO:0045761 regulation of adenylate cyclase activity
GO:0045980 negative regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0050804 modulation of synaptic transmission
GO:0051339 regulation of lyase activity
GO:0051350 negative regulation of lyase activity
GO:0051966 regulation of synaptic transmission, glutamatergic
GO:0052652 cyclic purine nucleotide metabolic process
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900372 negative regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0001640 adenylate cyclase inhibiting G-protein coupled glutamate receptor activity
GO:0001641 group II metabotropic glutamate receptor activity
GO:0005246 calcium channel regulator activity
GO:0008066 glutamate receptor activity
GO:0016247 channel regulator activity
GO:0098988 G-protein coupled glutamate receptor activity
Cellular Component GO:0014069 postsynaptic density
GO:0030424 axon
GO:0030425 dendrite
GO:0042734 presynaptic membrane
GO:0043197 dendritic spine
GO:0044309 neuron spine
GO:0045211 postsynaptic membrane
GO:0060076 excitatory synapse
GO:0097060 synaptic membrane
GO:0098793 presynapse
GO:0098794 postsynapse
GO:0099572 postsynaptic specialization
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04724 Glutamatergic synapse
Reactome R-HSA-420499: Class C/3 (Metabotropic glutamate/pheromone receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GRM3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GRM3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GRM3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0940.852
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2550.836
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1160.932
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0660.865
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0660.912
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3950.216
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GRM3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733711260.00629
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593710.226.80.00583
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.218.5-5.30.729
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.623.1-9.50.648
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.514.3-1.81
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRM3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRM3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRM3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRM3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GRM3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GRM3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGRM3
Nameglutamate receptor, metabotropic 3
Aliases GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location7q21.1-q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GRM3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GRM3.
ID Name Drug Type Targets #Targets
DB05096LY2140023Small MoleculeGRM2, GRM32